ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 14,772 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 14,772 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $13.75, for a total transaction of $203,115.00. Following the completion of the transaction, the director now directly owns 210,346 shares in the company, valued at $2,892,257.50. This represents a 6.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Laura Shawver also recently made the following trade(s):

• On Monday, December 2nd, Laura Shawver sold 97,244 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.56, for a total transaction of $1,318,628.64.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ:SPRY opened at $14.00 on Friday. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -27.45 and a beta of 0.88. The business’s 50 day simple moving average is $14.81 and its 200-day simple moving average is $12.17. ARS Pharmaceuticals, Inc. has a 12 month low of $5.01 and a 12 month high of $18.51.

Analysts Set New Price Targets

A number of equities research analysts recently commented on SPRY shares. Raymond James upgraded shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $18.00 to $22.00 in a research report on Tuesday, August 13th. Leerink Partners lifted their price target on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research note on Friday, September 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 price objective on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Finally, William Blair upgraded shares of ARS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $24.00.

Institutional Trading of ARS Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of ARS Pharmaceuticals by 37.0% in the 1st quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock worth $29,500,000 after buying an additional 779,969 shares in the last quarter. First Turn Management LLC purchased a new position in shares of ARS Pharmaceuticals during the 3rd quarter worth approximately $8,603,000. Jacobs Levy Equity Management Inc. raised its holdings in shares of ARS Pharmaceuticals by 78.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 653,048 shares of the company’s stock worth $9,469,000 after acquiring an additional 288,021 shares during the last quarter. Miura Global Management LLC acquired a new position in shares of ARS Pharmaceuticals in the third quarter worth $3,915,000. Finally, Wexford Capital LP acquired a new stake in shares of ARS Pharmaceuticals during the third quarter valued at $3,601,000. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.